Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + cetuximab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + cetuximab is a combination therapy being investigated for various cancers. Pembrolizumab is a PD-1 blocking antibody that helps the immune system detect and fight cancer cells by disrupting the interaction between PD-1 and its ligands. Cetuximab is an EGFR inhibitor that targets cancerous EGFR proteins and potentially slows down the growth of cancer cells. The combination may provide enhanced efficacy compared to either agent alone, particularly in head and neck squamous cell carcinoma (HNSCC) and colorectal cancer.
- Brand names
- OpdivoKeytruda
- Other names
- PD-1 inhibitors combinationPD1 inhibitors combinationPD 1 inhibitors combinationimmune checkpoint inhibitors combination
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + cetuximab.